Methyleugenol is a genotoxic carcinogen in mice and rats, the liver being the primary target tissue. Methyleugenol occurs in fennel and many herbs and spices. Furthermore, methyleugenol-containing plant extracts and chemically prepared methyleugenol are used as flavoring agents. We analyzed surgical human liver samples from 30 subjects for the presence of DNA adducts originating from methyleugenol using isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/ MS). Twenty-nine samples unambiguously contained the N 2 -(trans-methylisoeugenol-3′-yl)-2′-deoxyguanosine adduct. A second adduct, N 6 -(trans-methylisoeugenol-3′-yl)-2′-deoxyadenosine, was also found in most samples, but at much lower levels, in agreement with the results from experimental models. The maximal and median levels of both adducts combined were 37 and 13 per 10 8 nucleosides (corresponding to 4700 and 1700, respectively, adducts per diploid genome). This is the first demonstration of DNA adducts formed by a xenobiotic in human liver using UPLC-MS/MS, the most reliable method available. It has been estimated for diverse rat and mouse hepatocarcinogens that 50-5500 adducts per 10 8 nucleosides are present after repeated treatment at the TD 50 (daily dose that halves the probability to stay tumor-free in long-term studies). We conclude that the exposure to methyleugenol leads to substantial levels of hepatic DNA adducts and, therefore, may pose a significant carcinogenic risk.
Introduction
Methyleugenol (structural formula in Figure 1 ) is a secondary metabolite occurring in fennel and many herbs and spices, such as basil, pimento, laurel, anise and tarragon (1) . Moreover, essential oils rich in methyleugenol are used for flavoring foods and cosmetics. The usage of pure methyleugenol for this purpose has been banned in some countries (e.g. European Union), but not in others (e.g. USA).
Methyleugenol showed clear evidence of induction of hepatocellular carcinomas (HCCs) in both sexes of mice and rats (2, 3) . In addition, it induced tumors of the bile duct, glandular stomach, kidney, mesothelium, mammary gland and skin in some models (3) . It forms DNA adducts in tissues of rats and mice (4) (5) (6) . Methyleugenol and some of its hydroxylated metabolites are mutagenic in cells expressing appropriate sulfotransferases (SULTs), required for their activation to electrophilic metabolites (7) . Twenty out of 29 HCCs induced by methyleugenol in mice showed mutations in the tumor suppressor gene Ctnnb1, whereas such mutations were only found in 2 out of 22 spontaneous HCCs (8) , suggesting that mutagenicity is an important mechanism in the carcinogenicity of methyleugenol.
Using mass spectrometry and nuclear magnetic resonance spectroscopy, we recently identified the structure of the DNA adducts formed by reactive metabolites of methyleugenol in target cells of mutagenicity tests (Figure 1 ) (7) . We also demonstrated that the same adducts are formed in primary cultures of rat hepatocytes treated with methyleugenol (9) . Our method for adduct detection is based on isotopedilution ultra-performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS) with usage of isotope-labeled internal adduct standards ensuring specific and quantitative determination (7, 10) . In this study, we have analyzed surgical liver samples from 30 human subjects for the presence of methyleugenol DNA adducts.
Materials and methods

Chemicals and enzymes
Micrococcal nuclease from Staphylococcus aureus, phosphodiesterase (type II) from bovine spleen and alkaline phosphatase from calf intestine were purchased from Sigma-Aldrich (Taufkirchen, Germany (7).
Liver samples
Liver tissue samples were collected from 30 Caucasian individuals (18 males and 12 females) undergoing liver surgery at the Campus Virchow, University Medical Center Charité, Berlin, Germany, as described previously (11) . All liver samples were histologically examined and only non-tumorous tissue was used. Patient documentation included age, sex, medical diagnosis, presurgical medication, and alcohol and smoking habits. Samples from patients with hepatitis, cirrhosis or chronic excessive alcohol use were excluded. The collection of tissues and the adduct analysis were approved by the ethics committees of the Medical Faculty Charité, Berlin, and the University of Potsdam, Germany. For details on liver samples, see Supplementary Table S-I, available at Carcinogenesis Online.
Analysis of DNA adducts
Compared with our initial protocol (7) we have reduced the level of DNAhydrolytic enzymes per microgram of DNA to reduce costs (10) and increased the nominal amount of DNA analyzed per sample from 12.5 to 112.5 µg to improve detection. We have replaced the protein precipitation step after DNA digestion by liquid-liquid extraction to avoid coprecipitation of adducts with the protein and to reduce background signals in the UPLC-MS/MS analysis. Briefly, 12 mg (NH 4 ) 2 SO 4 was added to the hydrolyzates (300 µl) in order to facilitate the liquid-liquid extraction by reducing the hydration sphere of proteins. Then, the samples were extracted triply with an equal volume of water-saturated butanol. The pooled butanol phases were washed with butanolsaturated water (400 µl), evaporated to dryness under reduced pressure and redissolved in 25 µl of 75% methanol for UPLC-MS/MS analysis. DNA was isolated by phenol-chloroform extraction and, therefore, was contaminated with RNA (up to 57% of the total nucleic acids in the samples used). For the calculation of the actual amount of DNA used, we determined the ratio of 2′-deoxyguanosine and guanosine in the DNA hydrolyzates (before butanol extraction) by UPLC-MS/MS using 15 N-labeled nucleosides as internal standards.
Sample separation and analyte detection were carried out with an Acquity UPLC system equipped with an Acquity BEH-Phenyl column (1.7 µm, 2.1 100 mm) and a Xevo TQ triple quadrupole mass spectrometer (all from Waters, Eschborn, Germany). The ionization of the analytes occurred within an electrospray source operating in the positive ion mode. Quantification of the analytes was performed by isotope-dilution multiple reaction monitoring using the m/z transitions indicated in the first paragraph of the Results. The elution conditions and settings of the MS/MS detector have been published elsewhere (7) . In addition, all samples were analyzed by a different experimenter using a separate digestion reaction and a different gradient for the chromatography (Supplementary Material, available at Carcinogenesis Online).
Abbreviations: HCC, hepatocellular carcinoma; LC, liquid chromatography; MS/MS, tandem mass spectrometry; N 6 -MIE-dA, N 6 -(trans-methylisoeugenol-3′-yl)-2′-deoxyadenosine; N 2 -MIE-dG, N 2 -(trans-methylisoeugenol-3′-yl)-2′-deoxyguanosine; SULT, sulfotransferase; UPLC, ultra-performance liquid chromatography.
Results
General analytical features N
2 -MIE-dG and N 6 -MIE-dA eluted with retention times of 2.44 and 2.74 min, respectively. For each analyte and isotope-labeled standard (numbers marked with asterisk), three characteristic m/z transitions were available (7). They reflect the fragmentations indicated in Figure 1 . N 2 -MIE-dG was detected using the transitions 444. and phenylethyl group). The signals (peak areas) for these transitions were produced in a ratio of 100:63:59. The first transition was used as quantifier and the remaining transitions served as qualifiers. Similarly, N 6 -MIE-dA was detected using the transitions 428. 34 . From previous work we know that N 2 -MIE-dG adducts are formed at much higher levels than N 6 -MIE-dA. Its excess was nearly 50-fold in a SULT1A1-expressing Salmonella typhimurium strain treated with hydroxylated metabolites of methyleugenol (7) as well as in liver of methyleugenol-treated mice (Herrmann,K., Florian,S., Engst,W. and Glatt,H., unpublished result).
The limit of quantification of our original protocol was 3 N 6 -MIE-dA and 12 N 2 -MIE-dG adducts per 10 8 nucleosides using murine liver DNA spiked with varying levels of adduct standards. In this case, it was sufficient to use the quantifier transition, as non-spiked DNA could be used as a negative control. Such negative controls are not available when analyzing arbitrary human tissue specimens. Therefore, it is important to verify the quantifier signal by qualifier signals. In order to improve the sensitivity of the analysis for the present project, we increased the amount of DNA per analysis 9-fold. However, this modification led to a 70% decrease in the signals produced by the internal standards. Such effects, which may result from ion suppression in the presence of by-products, are common in mass spectrometry. Alternatively, adducts may have been coprecipitated in the protein precipitation step. Therefore, we replaced the precipitation step by liquid-liquid extraction. This modification did not only recover the full signal of the internal standards, but also reduced background signals in the chromatograms. Figure 2 presents the chromatograms for hepatic DNA from subject 17. It showed strong signals corresponding to the quantifier (trace A1) and both qualifiers (A2-3) of N 2 -MIE-dG. The relative intensities of these three signals (100:51:62) matched those of the internal standard (100:63:59). In a similar manner, although at a much lower level, quantifier (trace B1) and qualifier (B2-3) signals for N 6 -MIE-dA were detected. The level of N 2 -MIE-dG exceeded that of N 6 -MIE-dA 60-fold, which is similar to the ratio of these adducts formed by methyleugenol in experimental models. Taken together, this is incontestable evidence for the presence of hepatic methyleugenol DNA adducts in subject 17. Clear evidence for the presence of N 2 -MIE-dG adducts, although at lower levels, was obtained for 28 other subjects, based on the detection of all three m/z transitions ( Table I ). The chromatogram for the subject with the lowest adduct level (subject 16) together with the single subject showing no methyleugenol DNA adducts (subject 5) are presented in Figure 3 . None of the m/z transitions characteristic for N 2 -MIE-dG was seen with the latter subject (traces B1-B3). In the quantifier trace (B1), two clear, but small background peaks occurred in the vicinity (2.13 and 2.74 min) of the internal standard 
Detection of adducts in human liver samples
Adduct levels were determined from the signal size of the quantifier transition relative to that of the isotope-labeled internal standard. When sufficient material was available, two separate DNA digestions and adduct analyses were conducted. In this case both results are presented, separated by a slash. -, no signal detected. -MIE-dG adducts. Subject 5 was the only one providing a negative result. Subject 16 showed the lowest adduct levels among the remaining 29 subjects studied. DNA was spiked with isotope-labeled internal standards, digested to deoxynucleosides and subjected to UPLC-MS/MS analysis in the multiple reaction monitoring mode. Traces A1-3 and B1-3 represent characteristic m/z transitions of the analyte N 2 -MIE-dG in the hepatic samples, from subjects 16 and 5, respectively. A4 and B4 present the quantifier signals of the internal standard. Numbers indicate retention times and peak areas.
(2.45 min, trace B4), allowing an estimate of the limit of detection. A quantifier signal at 2.45 min exceeding 25% of that at 2.74 min would have been detected, implying that a possible adduct level was <0.1 per 10 8 nucleosides or 1/360 of the highest level observed (subject 17). Signals indicating the presence of N 6 -MIE-dA were observed in most samples, except those with low or undetectable N 2 -MIE-dG levels (Table I ). In agreement with experimental models, N 6 -MIE-dA adducts were present at much lower levels than those of N 2 -MIE-dG. There was a statistically highly significant linear correlation between the N 2 -MIE-dG and N 6 -MIE-dA levels in the 30 subjects studied (r 2 = 0.39, P = 0.0002). The relatively low correlation coefficient may be due to differential repair of both adducts and/or background signals. In conclusion, the presence of N 6 -MIE-dA adducts could be demonstrated, although an accurate quantification was not possible due to the low levels. The presence of this minor adduct, in addition to N 2 -MIE-dG, represents a further verification of the adduct formation by methyleugenol.
Reproducibility of adduct detection in human liver samples
Using the original protocol, 11 liver samples were analyzed in duplicate (Table I ). The levels of N 2 -MIE-dG determined in these duplicate analyses varied ≤1.2-fold for most samples. Larger variations (1.4-and 1.6-fold) with the N 2 -MIE-dG adduct were only observed in two liver samples with very low adduct levels. Because levels of N 6 -MIE-dA adducts were generally low, variation between duplicate determination was larger. On a later occasion, adduct levels in all hepatic samples were newly determined by another experimenter using modified chromatographic conditions (Supplementary Material, available at Carcinogenesis Online). The results for N 2 -MIE-dG (Supplementary Table S 
Discussion
DNA adducts link chemistry, which provides information on the nature of the causing agent, and toxicology, as the adducts represent the major primary damage that may lead to the induction of gene mutations. Isotope-dilution UPLC-MS/MS is the gold standard for the unambiguous identification and accurate quantification of specific adducts (12) . In this study, we demonstrate the abundant presence of adducts derived from methyleugenol in human hepatic DNA. The maximal and median levels of these adducts (N 2 -MIE-dG and N 6 -MIE-dA combined) were 37 and 13 per 10 8 nucleosides, corresponding to 4700 and 1700, respectively, adducts per diploid genome (6.6 × 10 9 base pairs). The mean daily intake of methyleugenol from food was estimated to 0.19 mg/kg body mass for Europe (1) . In an ongoing study, we treated mice with similar doses of methyleugenol. Single oral doses of 0.05 and 0.5 mg/kg body mass led to the formation of 7 and 22, respectively, adducts (N 2 -MIE-dG and N 6 -MIE-dA combined) per 10 8 nucleosides in the liver of wild-type animals. Somewhat higher values (17 and 86, adducts per 10 8 nucleosides) were reached in animals in which the endogenous Sult1a1 gene was knocked out and replaced by multiple copies of the human SULT1A1/1A2 gene cluster (Herrmann,K., Meinl,W., Florian,S., Engst,W. and Glatt,H., unpublished results). Therefore, it is plausible that the N 2 -MIE-dG and N 6 -MIE-dA adducts detected in the human liver specimens were indeed produced by methyleugenol present in the diet.
No data on dietary habits of the donors were recorded because the liver samples were collected for another purpose, the study of factors involved in biotransformation and transport of xenobiotics (11).
Other information on the patients (such as age, sex and presurgical medication) was available, although incomplete (Supplementary Table  S-I, available at Carcinogenesis Online). Apart from this incompletion, the number of subjects investigated was too low for any meaningful correlation analysis between adduct levels and other parameters. However, we noticed that the single subject without detectable methyleugenol DNA adduct (subject 5) was relatively young (22-yearold female). The other very young subject (subject 21), a 19-year-old male, was diagnosed with a HCC (the only one among the patients, ignoring some patients with unrecorded diagnosis). His adduct level (4.7 per 10 8 nucleosides) was also in the lower range. Nevertheless, these data are too weak to speculate about a possible accumulation of adducts with age and possible associations with HCC. We are going to study these aspects in a larger follow-up project.
Up-to-date, only a small number of different DNA adducts have been detected in human tissues. The adducts found in human hepatic DNA are listed in Table II . Many of them were detected using 32 P-postlabeling or antibodies raised against adducts. Although these methods are very sensitive, verification of the structure of the analyte and its accurate quantification are not always trivial, especially when adduct levels are low. Indeed, methyleugenol is the first xenobiotic for which formation of DNA adducts in human liver has been demonstrated using isotope-dilution UPLC-MS/MS, a method that is particularly reliable for unambiguous identification and quantification of analytes. However, this method was previously used for the demonstration of a small number of hepatic DNA adducts that may be formed by endogenous processes (15) . Thus, the levels of these adducts were markedly to marginally lower than those of the methyleugenol-derived adducts observed in this study.
HCC causes nearly 696 000 deaths per year worldwide (estimate for 2008) (16) . Chronic infection with hepatitis virus B or C and alcoholism are major predisposing factors (17) . Mutations in certain genes, in particular p53 and CTNNB1, are common in HCCs (18) . Therefore, it is probable that chemicals that induce DNA damage in liver are important for the induction of HCC in humans in addition to the predisposing factors mentioned, which enhance the turnover of liver cells.
Otteneder and Lutz (19) reviewed the literature on DNA adduct formation by rodent carcinogens in target tissues after repeated administration (for ≥10 days) near the TD 50 (dose that halves the probability to stay tumor-free in a long-term animal study). They found appropriate data for six and five compounds that induce liver tumors in rats and mice, respectively. The calculated adduct level 'responsible' for a 50% hepatocellular tumor incidence spanned from 53 to 2083 per 10 8 nucleosides in rats and from 812 to 5543 per 10 8 nucleosides in mice. It has to be added that most adduct levels used for these correlation study were determined using 32 P-postlabeling, a method that tends to underestimate the absolute adduct levels due to incomplete recovery (20, 21) . Nevertheless, the methyleugenol DNA adduct levels found in human liver (median 13 per 10 8 nucleosides) are sufficiently close to the levels observed for various heptocarcinogens at their TD 50 in rodents to be of concern. Therefore, our observations are alarming, demanding either a reduction of the exposure to methyleugenol or careful risk assessment taking into account our findings.
Supplementary material
Supplementary Tables S-I and S-II and Supplementary Material can be found at http://carcin.oxfordjournals.org/.
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